Business Context and Reporting Period
Company: Black Hawk Acquisition Corporation (Black Hawk)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter ended May 31, 2025
Business Overview: Black Hawk is a Cayman Islands exempted company formed as a "blank check" SPAC to effect a merger, share exchange, or asset acquisition. As of the reporting date, the Company had not commenced operations and generated no operating revenue. Its primary activities involve identifying a target for an initial business combination.
Key Development: On April 26, 2025, the Company entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. ("Vesicor"), a biotechnology company. The transaction values Vesicor at a pre-money equity value of $70 million and is expected to close in the fourth quarter of 2025.
Key Financial Metrics
| Metric | Three Months Ended May 31, 2025 | Six Months Ended May 31, 2025 | Balance Sheet (May 31, 2025) |
|---|---|---|---|
| Net Income | $520,542 | $1,178,921 | - |
| Operating Expenses | $247,598 | $356,367 | - |
| Interest Income (Trust Account) | $767,623 | $1,533,534 | - |
| Cash (Operating) | - | - | $72,914 |
| Investments in Trust Account | - | - | $73,362,798 |
| Total Assets | - | - | $73,502,321 |
| Total Liabilities | - | - | $2,666,043 |
| Working Capital | - | - | Deficit of $111,520 |
| Deferred Underwriting Fee | - | - | $2,415,000 |
Material Changes vs. Prior Period
- Net Income Growth: Net income for the three months ended May 31, 2025, increased to $520,542 from $310,936 in the same period in 2024. This increase is primarily driven by higher interest income earned on the Trust Account ($767,623 vs. $668,169).
- Expense Reduction: General and administrative expenses decreased to $217,598 for the three months ended May 31, 2025, compared to $335,259 in the prior year period.
- Trust Account Balance: Investments held in the Trust Account increased to $73,362,798 as of May 31, 2025, from $71,829,264 as of November 30, 2024, due to accrued interest.
- Target Company Deposit: A new liability of $250,000 "Due to target company" appeared on the balance sheet, representing non-refundable deposits received from Vesicor Therapeutics to cover transaction costs.
Outlook, Risks, and Management Commentary
- Business Combination Status: The proposed merger with Vesicor Therapeutics is subject to regulatory approvals, shareholder votes, and Nasdaq listing approval. The transaction is expected to close in Q4 2025.
- Extension Proposal: The Company filed an amendment to its proxy statement to extend the deadline to consummate a business combination from June 22, 2025, to December 22, 2026. Shareholders voted on this proposal in late June 2025 (meeting adjourned to June 27, 2025). If approved, the Sponsor must deposit funds into the Trust Account for each month of extension.
- Going Concern: Management has determined that conditions raise substantial doubt about the Company's ability to continue as a going concern. This is due to the working capital deficit and the uncertainty of completing a business combination within the required timeframe. The financial statements do not include adjustments that might result from this uncertainty.
- Liquidity: The Company has minimal operating cash ($72,914) and relies on the Trust Account for the business combination. It may require additional funding from the Sponsor or related parties to meet liquidity needs prior to the transaction.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of May 31, 2025.
Investor Verification Checklist
- Extension Vote Outcome: Verify if the shareholder vote to extend the combination deadline to December 2026 was approved and if the required extension deposits were made to the Trust Account.
- Transaction Closing Conditions: Monitor the status of regulatory approvals and Nasdaq listing approval required for the Vesicor Therapeutics merger.
- Liquidity Sufficiency: Assess whether the current operating cash balance ($72,914) is sufficient to cover expenses until the merger closes or if additional related-party loans are required.
- Internal Control Remediation: Review subsequent filings for updates on the remediation of ineffective disclosure controls and procedures.
- Redemption Risk: Evaluate the potential for public shareholders to redeem shares prior to the merger, which could impact the cash available for the transaction.